These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22191799)

  • 1. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
    Garnock-Jones KP
    Drugs; 2012 Jan; 72(1):109-32. PubMed ID: 22191799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landiolol: A Review in Tachyarrhythmias.
    Syed YY
    Drugs; 2018 Mar; 78(3):377-388. PubMed ID: 29470800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
    Wiest DB; Haney JS
    Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis.
    Ollila A; Vikatmaa L; Sund R; Pettilä V; Wilkman E
    Ann Med; 2019 Feb; 51(1):17-27. PubMed ID: 30346213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia.
    Oxorn D; Knox JW; Hill J
    Can J Anaesth; 1990 Mar; 37(2):206-9. PubMed ID: 1968784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Esmolol--beta-adrenergic blocking agent with ultrashort action].
    Marenović T; Stojiljković MP; Marković M
    Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():65-70. PubMed ID: 18193815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
    Ko WJ; Chu SH
    J Am Coll Cardiol; 1994 Feb; 23(2):302-6. PubMed ID: 7905013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Benfield P; Sorkin EM
    Drugs; 1987 Apr; 33(4):392-412. PubMed ID: 2885168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
    Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
    Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular and antiarrhythmic effects of esmolol in children.
    Trippel DL; Wiest DB; Gillette PC
    J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
    Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
    Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
    Blanski L; Lutz J; Laddu A
    Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials.
    Yu SK; Tait G; Karkouti K; Wijeysundera D; McCluskey S; Beattie WS
    Anesth Analg; 2011 Feb; 112(2):267-81. PubMed ID: 21127279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals.
    Muszkat M; Hoofien A; Orlanski-Meyer E; Makhoul H; Porat E; Davidson EM; Blotnick S; Caraco Y
    Pharmacogenet Genomics; 2013 Jan; 23(1):25-8. PubMed ID: 23114278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.